Best pharmaceutical companies in Massachusetts

AMAG Pharmaceuticals is a biopharmaceutical company, which utilizes the technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and imaging agents to aid in the diagnosis of cancer and cardiovascular disease. The Company manufactures and sells two approved products, Feraheme (ferumoxytol) Injection for intravenous (IV) and GastroMARK. On June 30, 2009, Feraheme was approved for marketing in the United States by the United States Food and Drug Administration (FDA), for use as an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD).

ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Targeted Antibody Payload (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; IMGN901, a Phase I clinical trial product to treat hematological malignancies, including multiple myeloma, small-cell lung cancer, Merkel cell carcinoma, and other cancers of neuroendocrine origin; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkin's lymphoma; and IMGN388 and BIIB015, which are in Phase I clinical trials for the treatment of solid tumors. The company's products also comprise BT-062, a Phase I clinical trial product targeting multiple myeloma; SAR566658, a preclinical trail product for the treatment of breast, ovarian, and other solid tumors; SAR650984, a preclinical trail product to treat hematological malignancies; and TAP and other compounds. It has licensing or collaboration agreements with sanofi-aventis; Genentech, Inc.; Biotest AG; Bayer HealthCare AG; Biogen Idec; Amgen, Inc.; Centocor, Inc.; Cytovance Biologics LLC; Laureate Pharma, Inc.; BioInvent International AB; Diosynth RTP, Inc.; and Societa Italiana Corticosteroidi S.r.l. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.

Cubist Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company markets CUBICIN (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides in the United States. It began promoting MERREM I.V. (meropenem for injection) in the U.S. in July 2008. MERREM is an established spectrum antibiotic developed by AstraZeneca. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials; CONSERV-1 and CONSERV-2 for the reduction of blood loss during cardiac surgery; and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the company, in collaboration with Alnylam Pharmaceuticals, Inc., has a pre-IND and a Phase 2 program underway in novel treatments for respiratory syncytial virus infections using Alnylam's RNA-interference technology. Cubist was founded in 1992 and is headquartered in Lexington, Massachusetts.

EMD Millipore Corporation provides solutions and services for the research, development, and production of biotechnology and pharmaceutical drug therapies. The company offers analytics and sample preparation products, such as chromolith products, test strips, reference materials, and disinfection controls; biopharmaceutical manufacturing products, such as depth filters, prepacked chromatography columns, resins, and ultrafiltration cassettes; industrial microbiology products that include EZ-products, microbial air monitoring systems, microbial contamination detectors, and granulated media pouches; and IVD/OEM materials and reagents, including bulk and custom antibodies, blood typing monoclonal antibodies, microspheres, and OEM membranes. It also offers life science research products, including antibodies and assays, sterile and non- sterile filtrations, and biomarkers and immunoassays; and reagents, chemicals, and labware products, such as solvents, organic synthesis, and lab cleaning equipment, as well as salts, acids, and caustics. In addition, the company offers small molecule pharmaceuticals products that include silica excipients, polyvinyl alcohols, raw materials, and meglumines; and water purification products, including integral and advantage water purification systems, watercare pacts, and e-solutions. Further, it offers product related services for pharmaceutical research and biotechnology, pharmaceutical, academic, government, clinical, industrial, and research markets worldwide. EMD Millipore Corporation also offers products online. The company was formerly known as Millipore Corporation and changed its name to EMD Millipore Corporation in July 2010. As a result of acquisition of Millipore Corporation by Merck KGaA, its name got changed. The company was founded in 1954 and is based in Billerica, Massachusetts with manufacturing sites and offices worldwide. As of July 15, 2010, EMD Millipore Corporation operates as a subsidiary of Merck KGaA.

Alnylam (Nasdaq: ALNY) is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.

ARIAD is a Cambridge, Massachusetts-based biotechnology company focused on cancer. We are a cohesive team of talented people from diverse backgrounds with a shared vision: We seek to transform the lives of patients with breakthrough cancer medicines. This is our purpose. This is our passion. This is our promise.

Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.

Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company, engages in developing and marketing human medicines. It engages in developing a pipeline of clinical candidates in the areas of gastrointestinal diseases, cardiovascular diseases, pain, and inflammation. The company's operationally independent subsidiary, Microbia Inc., engages in developing and commercializing bioprocesses for use in pharmaceuticals, foods, and specialty and industrial chemicals. Ironwood Pharmaceuticals, Inc. was formerly known as Microbia, Inc. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts.

Learn how we develop, manufacture and commercialize precision diagnostics and radiopharmaceuticals to Find, Fight and Follow disease.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, design, and development of therapies for the treatment of diseases in the areas of autoimmunity and cancer. It develops MM-093, a human alpha-fetoprotein for the treatment of patients with rheumatoid arthritis and psoriasis; and MM-121, a human monoclonal antibody and therapeutic to block signaling of the ErbB3 receptor. Merrimack Pharmaceuticals, Inc. was formerly known as Atlantic BioPharmaceuticals, Inc. The company was founded in 1993 and is based in Cambridge, Massachusetts.

Vertex Pharmaceuticals is a biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain.

Alexion is a global biopharmaceutical company that focuses on serving patients and families affected by rare diseases through the innovation, development, and commercialization of life-changing therapies. This company was established in 1992. Alexion has 2,500 passionate and dedicated employees serving patients in 50 countries around the world. They have more than one billion dollars of reported revenues.

Haemonetics specializes in blood processing technology.

Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. The company is using ribonucleic acid interference (RNA) technology platform to develop its products. The product candidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others.

Capitalizing on breakthrough synthetic chemistry, Tetraphase Pharmaceuticals is leveraging a dynamic drug engine targeted at several significant disease categories.

Cytel is a multinational statistical software developer and contract research organization, headquartered in Cambridge, Massachusetts, USA.

Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans. This results in a diversified product pipeline of complex generic, follow-on biologic and novel drugs. The Company's two most advanced complex generic product candidates target marketed products, which were originally approved by the United States Food and Drug Administration as New Drug Applications. M-Enoxaparin is designed to be a generic version of Lovenox (enoxaparin sodium injection), a low-molecular weight heparin used to prevent and treat deep vein thrombosis. Its second major generic product candidate is M356, a generic version of Copaxone (glatiramer acetate injection), a drug that is indicated for the reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis.

PAREXEL International Corporation, a biopharmaceutical services company, provides clinical research, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology, and medical device industries worldwide. The company operates in three segments: Clinical Research Services (CRS), PAREXEL Consulting and Medical Communications Services (PCMS), and Perceptive Informatics (Perceptive). The CRS segment offers clinical trials management, observational studies, patient/disease registries and post-marketing surveillance, data management and biostatistics, epidemiology and health economics/outcomes research, clinical logistics, pharmacovigilance, and clinical pharmacology, as well as related medical affairs, patient recruitment, and investigator site services. This segment manages various aspects of clinical trials, including study and protocol design, case report form design, paper or electronic questionnaires design, patient enrollment, study monitoring and data collection, data analysis, report writing, and medical services. The PCMS segment provides technical expertise and advice in various areas, such as drug development, regulatory affairs, product pricing and reimbursement, and good manufacturing practice compliance consulting; and market development, product development, and targeted communications services in support of product launch. Its consultants also identify alternatives and propose solutions to address clients' product development, registration, and commercialization issues. In addition, this segment provides reimbursement and market access services. The Perceptive segment provides information technology solutions comprising medical imaging and systems integration services; ClinPhone RTSM, CTMS, and DataLabs EDC products; Web-based portals; and patient diary applications. The company was founded in 1983 and is headquartered in Waltham, Massachusetts.

They design and deliver smart-touch, omnichannel solutions to engage patients, and drive treatment initiation and adherence. Since 2008, Human Care Systems has worked with biopharma brand teams to implement programs that result in enhanced patient experiences and improved outcomes. With a 10:1+ ROI, their programs focus on distribution management, clinician support, patient support, safety management, and real-world evidence collection and use. Human Care Systems is a global company with 16 offices worldwide, servicing over 100 different patient populations.

Clinical Data, Inc. is focused on the development and commercialization of therapeutics, with two compounds in the areas of central nervous system and cardiovascular disorders. The Company's late-stage drug candidate is vilazodone, a dual-acting selective and potent serotonin reuptake inhibitor and serotonin receptor 1A (5-HT1A) partial agonist for the treatment of major depressive disorder (MDD). The Company's second late-stage drug candidate is apadenoson, trademarked Stedivaze, a selective adenosine receptor 2A (AR2A) agonist and coronary vasodilator in Phase III of clinical development for use in nuclear Single Photo Emission Computed Topography (SPECT) myocardial perfusion imaging. The Company also provides the FAMILION family of genetic tests for inherited cardiac syndromes, including cardiac channelopathies and cardiomyopathies. On September 30, 2009, the Company purchased all the assets of Epix Pharmaceuticals, Inc. (Epix).

Agios Pharmaceuticals is a biopharmaceutical company, discovers and develops therapeutics in the field of cancer metabolism. It also develops drugs that focus on glycolysis, fatty acid metabolism, and autophagy. The company's therapeutics are used in the areas of autoimmune, inflammatory, and neurological diseases. Agios Pharmaceuticals was formerly known as CANCER METABOLISM THERAPEUTICS And changed its name to Agios Pharmaceuticals In April 2008. The company is based in Cambridge, Massachusetts.

EyePoint Pharmaceuticals, Inc., is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders.

Glympse Bio is developing a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases. The company's technology uses precisely engineered diagnostic agents that interrogate the body for certain disease states, and then carry the message to the urine for analysis. Glympse Bio's platform technology was originally developed at MIT, and is founded by a team of world renowned experts in nanomedicine and biomedical engineering.

Enanta Pharmaceuticals, Inc., a research and development company, engages in the discovery, development, and promotion of small molecule drugs in the areas of anti-infective. It develops protease, NS5A, polymerase, and cyclophilin-based inhibitors for the treatment of hepatitis C virus (HCV). The company also develops ABT-450/r, an oral protease inhibitor for the treatment of hepatitis C (HCV) infection. In addition, it develops Bicyclolides, a macrolide antibiotic, which overcomes bacterial resistance; and EDP-420, a bicyclolide antibiotic for the treatment of community-acquired pneumonia. The company's antibacterial focus areas include superbugs, respiratory tract infections, and intravenous and oral treatments for hospital and community MRSA. The company has strategic alliances with Abbott Laboratories; and Shionogi & Co., LTD. Enanta Pharmaceuticals, Inc. was formerly known as NovirX, Inc. and changed its name to Enanta Pharmaceuticals, Inc. in May 1999. The company was founded in 1998 and is based in Watertown, Massachusetts.

Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce's proprietary product engine is driving this transformational approach, which has the potential to drive significantly more durable responses to treatment, extending and improving patients' quality of life. Founded by world leaders in immunobiology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures.

Maximize the value of your clinical data with our software & services that deliver faster insights from data acquisition through to analytics. Learn more!

Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products. Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. It was founded in 2013 and is headquartered in Cambridge, Massachusetts, the United States with a growing site in Boulder, Colorado.

FORMA Therapeutics is a biopharmaceutical company integrating transformative biology and chemistry to unlock targets and pathways that have been validated through genomic medicine as root causes or major drivers of human cancers. FORMA's approach to accessing such high value drug targets, many of which pose significant challenges to conventional discovery approaches, is rooted in the concerted integration of its innovative drug discovery technologies and oncology expertise, enabling screening, discovery and rational development of a generation of small molecule drug candidates with cellular mechanisms of action. FORMA is building a pipeline of therapeutics directed at Achilles heels in human cancers, such as key targets associated with cancer stem cells, tumor cell metabolism, programmed cell death or epigenetic disease mechanisms. FORMA builds on the vision of its academic founders: Stuart Schreiber, Todd Golub and Michael Foley, each of the Broad Institute of Harvard and MIT. FORMA leverages its innovative drug discovery platform to address challenging targets and develop a robust internal pipeline of breakthrough oncology drugs.

Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of proprietary, late stage pharmaceutical products. These products address the growing problems associated with non-medical use and abuse of prescription drugs through formulation based improvements protected by intellectual property (IP). Collegium is focused on building a portfolio of products for the treatment of chronic pain that possess tamper-resistant features and provide extended-release delivery using its patent protected DETERx™ formulation platform.

Karyopharm Therapeutics is a biopharmaceutical company focusing on the development of novel drugs for the treatment of cancer, inflammation and diseases related to cell proliferation. Karyopharm Therapeutics is developing small molecule drugs that will modulate the activity of critical pathways in cancer, inflammation, and cell proliferation (e.g. FOXO, NFкB, P53, pRB) by targeting the nuclear pore complex machinery, which controls the import and export of proteins between the nucleus and cytoplasm. To successfully control transport through the nuclear pore complex, the company will use its unique technology platform, developed by Sharon Shacham, to identify novel small molecules, optimize them into clinical candidates, and to evaluate them in subsequent human clinical studies.

H3 Biomedicine is a privately held, uniquely structured oncology discovery enterprise. At H3, they seek to become a prolific source of new drugs that treat more human cancers with greater success. H3 Biomedicine is applying the expertise of leading scientists to the integration of insights from cancer genomics with innovative capabilities in synthetic chemistry and tumor biology to pursue patient-based, genomics-driven, small molecule drugs, which represent the most promising current opportunity in cancer therapeutics.

DUSA Pharmaceuticals, Inc. (NASDAQGM: DUSA) is a fully integrated specialty pharmaceutical company focused primarily on the development and marketing of its Levulan photodynamic therapy (PDT) technology platform used in conjunction with it's proprietary light source, the BLU-U Blue Light Photodynamic Therapy Illuminator. Levulan Kerastick (aminolevulinic acid HCl) for Topical Solution, 20% in combination with the BLU-U is approved by the U.S. Food and Drug Administration for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp. Actinic Keratosis is the most frequently diagnosed skin disease by U.S. dermatologists. PDT is a two part process in which the target cells are made extremely sensitive to light and then exposed to blue light, which destroys the cells. The BLU-U, as a stand alone device, uses light to treat mild to moderate inflammatory acne. DUSA is based in Wilmington, MA.

Charles River Laboratories International, Inc. provides solutions that accelerate the drug discovery and development process, including research models and associated services, and outsourced preclinical services. Segments The company has two segments: Research Models and Services (RMS) and Preclinical Services (PCS), which includes Phase I clinical services. RESEARCH MODELS AND SERVICES (RMS) The company supplies research models to the drug development industry. With approximately 150 different strains the company engages in the production and sale of research models, principally genetically and virally defined purpose-bred rats and mice. It also provides various related services that are designed to assist customers in supporting the use of research models in drug development. With multiple facilities located on three continents (North America, Europe and Asia (Japan)), the company maintains production centers, including a total of approximately 180 barrier rooms or isolator facilities located near its customers. RMS segment comprises Research Models, Research Model Services, and other related products and services

Hillcrest Educational Centers, Pittsfield, MA. The Hillcrest Educational Centers in the Berkshires including Hillcrest Educational Centers Lenox, MA and Hillcrest Educational Centers Great Barrington, MA providing students with autism treatment and hig...

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics/pharmaceuticals to treat cardiovascular and metabolic diseases. It develops lomitapide/AEGR-733, a microsomal triglyceride transfer protein inhibitor small molecule drug for decreasing serum lipids, including cholesterol and triglycerides, as well as to treat atherosclerosis, dyslipidemia, obesity, and pancreatitis. The company also focuses on products for the evaluation and treatment of hyperlipidemia. Aegerion Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Bridgewater, New Jersey.

Pharmaceutical Strategies is a recruiting firm that specializes in the placement of professionals in pharmacies, hospitals, healthcare organizations and life sciences companies. We offer contract and direct hire services and work all over the U.S. Over the last 10 years, we have become a premier provider of talent and in 2014, we were awarded Inavero's "Best of Staffing for Client Satisfaction" Award.

Infinity Pharmaceuticals, Inc. engages in the discovery and development of medicines for the treatment of cancer and related conditions in the United States. Its lead product candidate includes IPI-504 (retaspimycin hydrochloride), an intravenously-administered small molecule inhibitor of heat shock protein 90 (Hsp90). The company is conducting an international Phase II clinical trial of IPI-504 in combination with Herceptin in patients with HER2-positive metastatic breast cancer; a Phase II clinical trial of IPI-504 in patients with advanced non-small cell lung cancer; and a Phase I clinical trial of IPI-504 in combination with Taxotere in patients with advanced solid tumors. Its products under Phase I clinical trial comprise IPI-493, an orally-delivered inhibitor of Hsp90, in patients with advanced solid tumors; IPI-926 for patients with advanced and/or metastatic solid tumors; and IPI-940, an orally-delivered inhibitor of fatty acid amide hydrolase for the treatment of neuropathic and inflammatory pain. Infinity Pharmaceuticals has strategic alliance agreements with Purdue Pharmaceutical Products L.P. and Mundipharma International Corporation Limited; an agreement with MedImmune, Inc. to develop and commercialize cancer drugs targeting Hsp90 and the hedgehog pathway; and a collaboration agreement with Novartis Institute for BioMedical Research, Inc. to discover, develop, and commercialize drugs targeting Bcl protein family members for the treatment of cancers. The company is headquartered in Cambridge, Massachusetts.

Proteostasis Therapeutics is discovering and developing novel small molecule therapeutics designed to control the body's protein homeostasis, or Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases. These novel therapies, or Proteostasis Regulators, are designed to treat multiple genetic and degenerative disorders associated with deficiencies of the Proteostasis Network, such as emphysema, type II diabetes, Alzheimer's Disease and Huntington's Disease.

Ora is the world's leading full-service ophthalmic CRO and product development firm with offices in the United States, the United Kingdom and Japan. Over the past 40 years, they helped their clients earn 43 product approvals. They support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market. Ora's pre-clinical and clinical models, unique methodologies and regulatory strategies have been refined and proven across thousands of projects. They bring together the world's most extensive and experienced team of ophthalmic experts and R&D professionals to maximize the value of new product initiatives.

&D risk, time and expense.

Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression.

Juniper Pharmaceuticals (Nasdaq: JNP) is developing therapeutics that address unmet medical needs in women's health. Their current pipeline leverages the 505(b)(2) regulatory pathway with new formulations of existing pharmaceuticals. The Company has a successful history in developing pharmaceutical products, including Crinone 8% (progesterone gel), which is commercially available in the United States and over 90 countries around the world. Their current intravaginal ring (IVR) product candidates are: JNP-0101, an oxybutynin IVR for the treatment of overactive bladder in women; JNP-0201, a combination estrogen + progesterone IVR for menopausal symptoms; and, JNP-0301, a progesterone IVR for the prevention of preterm birth in women with a short cervical length at mid-pregnancy. They are leveraging the in-house pharmaceutical development, clinical trial supply manufacturing, and analytical capabilities of Juniper Pharma Services to advance an internal product pipeline, while also providing valuable intellectual property-related consultative services to their pharmaceutical industry customers. Juniper is positioned for success with a highly experienced leadership team in combination with a solid balance sheet and strong cash flows to advance a proprietary pipeline for long term value creation.

Berkshire Medical Center is a private, non-profit 302-bed community teaching hospital in Pittsfield, Massachusetts affiliated with the University of Massachusetts Medical School.

Spectrawave is a medical device company that develops optical diagnostic and therapeutic devices. It enhances the diagnosis and treatment of cardiovascular diseases and primarily operates in the diagnostic equipment, medical business/industry. The Waltham, Massachusetts based company was founded in 2017.

Paratek Pharmaceuticals, Inc. is a privately held biopharmaceutical company headquartered in Boston, MA, which is engaged in the discovery and commercialization of new therapeutics that treat life threatening infectious and other serious diseases.

Provide the best service to our clients, volunteers, donors, and our community by striving for excellence every day.

Radius Health Care, Inc. provides nursing care facility. The company was founded in 1997 and is based in Southborough, Massachusetts.

Nference AI technology enables knowledge synthesis from unstructured text and structured biomedical databases. It synthesizes exponentially growing biomedical knowledge to solve urgent healthcare problems. The company uses state-of-the-art neural networks for real-time, automated extraction of insights by triangulating unstructured and structured information from the biomedical literature as well as from large scale molecular and real-world datasets. The platform enables a diverse set of applications ranging from R&D to commercial strategy and operations in the life sciences ecosystem. Nference was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Acusphere is a specialty pharmaceutical company, primarily focused on the development of Imagify™ (perflubutane polymer microspheres) injectible suspension, a cardiovascular drug for the detection of coronary artery disease. Acusphere is in the process of seeking regulatory approval of Imagify in Europe, and negotiating a Special Protocol Assessment with FDA for an additional trial required for U.S. approval. Imagify was created using Acusphere's proprietary porous microparticle technology, which was also used to create three other drugs which have begun clinical development - AI-525 for acute pain, AI-850 for oncology and AI-128 for asthma. AI-525 and AI-850 were sold to Cephalon in transactions totaling $31 million. AI-128 was developed in collaboration with Elan, who contributed $7.5 million to the program. Acusphere's technology has the potential to create a wide variety of new drugs by reformulating hydrophobic drugs and creating sustained release formulations of existing drugs.

AZTherapies is an advanced clinical-stage biopharmaceutical company developing novel therapies that aim to fundamentally change neurodegenerative disease progression, extending normal cognition and function and improving quality of life in the aging population. Advancing a growing pipeline to treat patients with few therapeutic options, the company's lead candidate, ALZT-OP1, is built on a multi-modal approach that recognizes neuroinflammation as a root cause of serious neurodegeneration and seeks to stop or slow the progression of the disease. The Phase 3 COGNITE trial in early Alzheimer's disease is fully enrolled and expected to complete in late 2020. Following the lead program, AZTherapies is advancing candidates for the treatment of post-ischemic stroke cognitive impairment, amyotrophic lateral sclerosis (ALS), and other indications. The company was headquartered in 2011 by David R. Elmaleh in Boston, Massachusetts.

Hotspot Therapeutics derives medical solutions from natural solutions.

IWP is a national home delivery pharmacy service working on behalf of injured individuals. As an advocate for those who have been injured, IWP takes the financial burden out of the prescription process by shipping medications directly to the patient and collecting payment from the insurance company. There are minimal out-of-pocket expenses for the patient, physician, or attorney on approved claims.* they reduce time and energy spent on prescriptions and paperwork while ensuring injured individuals get the continuous quality care they deserve.

Pharmalucence, Inc. is primarily engaged in manufacturing, fabricating, or processing drugs in pharmaceutical preparations for human or veterinary use. The greater part of the products of these establishments are finished in the form intended for final consumption, such as ampoules, tablets, capsules, vials, ointments, medicinal powders, solutions, and suspensions. Products of this industry consist of two important lines, namely: (1) pharmaceutical preparations promoted primarily to the dental, medical, or veterinary professions, and (2) pharmaceutical preparations promoted primarily to the public.

PerSeptive Biosystems, Inc. develops, manufactures, and markets instrumentation systems and consumable products for the purification, analysis, and synthesis of biomolecules. The company's products are used in the life sciences industry for the discovery, development, and manufacture of pharmaceutical products. It engages in developing products in the fields of chromatography, immunoassay, biological mass spectrometry, solid-phase synthesis, and microfluidic assay devices. PerSeptive Biosystems, Inc. was formerly known as Synosys Corporation. The company was founded in 1989 and is based in Framingham, Massachusetts. PerSeptive Biosystems, Inc. operates as a subsidiary of Life Technologies Corporation.

Sanofi Biosurgery Inc. develops and markets surgical devices and biologics for osteoarthritis pain relief, adhesion reduction, cartilage repair, and severe burn treatment. Its products include Synvisc, Synvisc-One (hylan G-F 20), Carticel (autologous cultured chondrocytes), MACI (Matrix-induced Autologous Chondrocyte Implantation), Seprafilm, and Epicel (cultured epidermal autografts). Sanofi Biosurgery Inc. was formerly known as Genzyme Biosurgery Corporation. As a result of acquisition of Genzyme Biosurgery Corporation by Sanofi, Genzyme Biosurgery Corporation name was changed. The company was founded in 2000 and is based in Cambridge, Massachusetts. Sanofi Biosurgery Inc. operates as a subsidiary of Sanofi.

Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high, sustained local drug concentrations with reduced systemic exposure and are delivered in a patient friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept, while establishing R&D collaborations with select partners to improve products in their pipelines.

Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020.

Ascend Group Partners is an agriculture company that offers an integrated cannabis cultivator, processor, and dispensary operator. It seeks to foster a robust and inclusive cannabis industry through a premium, unmatched customer-focused retail experience. It was founded in 2018 and headquartered in Boston, Massachusetts.

PARx Solutions, Inc. provides a Web-based prior authorization support (PASS) system for supporting physicians and patients. The company's PASS services improve and simplify the prior authorization process for physicians, office staff, and patients. It enables access for the appropriate utilization of therapeutics and products by standardizing the medical necessity request process. PARx Solutions, Inc. was formerly known as Apricot Health Strategies, Inc. The company is based in Los Altos, California.

Aciex is focused on developing first-in-class products to fill unmet needs for ophthalmic therapeutics-products that will permit us to build a sustainable ophthalmic franchise. They believe their company is unique in both concept and products and timely in terms of the market, and they are pleased you have chosen to learn more about Aciex.

Anexon, Inc., a pharmaceutical company, develops therapeutics for cardiovascular diseases. The company is based in Cambridge, Massachusetts.

MOLECULAR BIOMETRICS & GASTRONOMY Since 2005 We show you how to do it and you follow us Know More Gerard Depardieu “Cooking is not difficult. Everyone has taste, even if they don't realize it. Even if you're not a great chef, there's nothing to stop yo...

South Shore Elder Services, Inc. is the designated Aging Services Access Point and Area Agency on Aging for eleven communities on the South Shore. We have been providing services to older people and their caregivers in Braintree, Cohasset, Hingham, Hol...

We are game changers. Value creators. Innovators. Leaders. We obsessively look for new and better ways to ensure the short- and long-term affordability and availability of the portfolio we manage. We do it for the millions of people who rely on gene...

Working collaboratively with the surgical community, Cambridge Endo is committed to developing and delivering hand-held instruments that enable easy access and unparalleled control.

EPIX Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics through the use of its proprietary silico drug discovery technology to treat diseases of the central nervous system and lung conditions. Its therapeutic product candidates in development PRX-08066, a small-molecule inhibitor that completed Phase II clinical trials for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with chronic obstructive pulmonary disease; and PRX-07034, which completed Phase I studies for the treatment of cognitive impairment associated with schizophrenia. The company also offers Vasovist, an injectable intravascular contrast agent to provide enhanced imaging of the vascular system using magnetic resonance angiography. It has collaborations with SmithKline Beecham Corporation, Amgen Inc., and Cystic Fibrosis Foundation Therapeutics, Incorporated. The company was formerly known as EPIX Medical, Inc. and changed its name to EPIX Pharmaceuticals, Inc. in 2004. EPIX Pharmaceuticals, Inc. was founded in 1988 and is based in Lexington, Massachusetts. As of July 20, 2009, EPIX Pharmaceuticals, Inc. is in liquidation.

USA's longest running cohort study • Located in Framingham, MA • A project of @BUMedicine & @NIH_NHLBI Account is maintained by FHS contract staff(BUMC).

GTC Securities Corporation is primarily engaged in the purchase, sale, and brokerage of securities; and those, generally known as investment bankers, primarily engaged in originating, underwriting, and distributing issues of securities.

Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.

Asahi Kasei Corporation is a multinational Japanese chemical company.

To provide quality, efficient, and effective human services, which improve the lives of people.

Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. Its products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic and biocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma.

X-COR Therapeutics is a Boston based medical device company creating the first commercially available CO2 removal device that uses ultra-low-blood flows for a cheaper, safer, and more accessible treatment for acute respiratory failure. X-COR was the runner-up in the 2018 Harvard President's Innovation Challenge with its device, a novel consumable hybrid cartridge that removes CO2 from patients' blood with less invasive procedures than high-flow alternatives. X-COR is part of the 2018 MedTech Innovator and MassChallenge cohorts. X-COR's core technology is a patent-pending medical device that allows physicians to remove excess CO2 from patients who are in symptomatic lung failure and its accompanying control algorithm that is based on machine-learning techniques. The system is compatible with existing medical device infrastructure for ease of use and deployment. Unlike other technologies to treat lung failure, X-COR uses a hybrid approach that allows patients' blood to be drawn at 3 L/min flows and highly specialized physicians.

This domain may be for sale!

Village Fertility Pharmacy is a specialty pharmacy dedicated to offering the best service and education to infertility patients and clinics. In operation for more than 30 years, Village has developed a deep understanding of the complicated nature of infertility treatments and the unique needs of infertility patients.

Akebia Therapeutics, Inc., a pharmaceutical company, focuses on treatments for ischemia and improvement of vascular disease. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. The company offers Omacor for hypertriglyceridemia; and Actonel for osteoporosis. Its products include prolyl hydroxylase enzyme and phosphatase enzyme. Akebia Therapeutics, Inc. was founded in 2007 and is based in Cincinnati, Ohio.

Frenova, the foremost name in renal research, offers contract clinical research services, starting with the CKD/ESRD patient in mind.

Myomo, Inc., a medical technology company, develops Myoelectric prosthetic technology to powered bracing devices that restore an individual's mobility. It offers Myomo mPower 1000, a portable lightweight functional arm brace for use in home and in clinical settings, which restores movement to a weakened arm as a result of neuromuscular damage caused or due to brain injury, including stroke, spinal cord injury, multiple sclerosis, cerebral palsy, muscular dystrophy, and traumatic brain injury. The company also provides PERL (Push, Eat, Reach, Lift) technique, a set of research-based treatment plans that integrate the mPower 1000 into functional repetitive task practice programs aiming to increase the functional activity; myGames, a virtual reality-based therapeutic training system to encourage brain injured patients with upper limb motor disorders to practice physical exercises; and myProgress, an Android-based connected health platform that tracks and measures progress while using the mPower 1000. Its mobility system is designed to enable individuals to self-initiate and control the movement of partially paralyzed limbs using their own muscle signals. The company serves medical professionals, patients, and caregivers in the United States. Myomo, Inc. was formerly known as Active Joint Brace. The company was founded in 2004 and is based in Cambridge, Massachusetts.

NuOrtho Surgical, Inc. is a highly innovative early stage medical device company developing revolutionary technology for the healthcare industry. Our focus is to preserve the normal, healthy tissue of patients that today is damaged as a by-product of current treatments.

Centrexion Therapeutics develops non-opioid therapies for chronic pain.

Outlier Biopharma is a cannabis consulting company focused on providing offshore and outsourced cultivation, extraction, and production solutions to businesses in the medical cannabis industry.

MitraSpan, Inc. was incorporated in 2012 and is based in Belmont, Massachusetts.

ThePoliticalGuide.com is political guide intended to provide impartial information on candidates, elections, and representatives.

To create new treatments for rare diseases.

Silver Therapeutics is a retail company that specializes in the manufacturing, distribution, and selling of cannabis-based products. It offers a diverse selection of high-quality cannabis products, friendly & knowledgeable staff, and reasonable prices.

Cambridge Heart, Inc. engages in the research, development, and commercialization of products for the non-invasive diagnosis of cardiac disease in the United States and internationally. The company provides Heartwave II System, which is used to perform a Microvolt T-Wave Alternans (MTWA) test; Micro-V Alternans Sensors, which are single patient use, multi-segment electrodes that are used in MTWA tests; and CH2000 Cardiac Stress Test System, a diagnostic system to support various standard and physician-customized protocols for the conduct and measurement of cardiac exercise stress testing. It markets and sells its products primarily to cardiology group practices, physicians, hospitals, and research institutions. The company markets its products internationally through independent distributors.

EyeGate Pharma is developing a proprietary platform of medicines to treat diseases of the eye using its unique, non-invasive, iontophoretic drug-delivery system called EyeGate II. This proprietary technology platform is based on over 10-years of development at the Bascom Palmer Eye Institute at the University of Miami and has been tested extensively in both preclinical and human studies in Europe. Because of the human eye's special anatomy, effective delivery of medicines to treat chronic disease or diseases in the mid and posterior segments of the eye is less than adequate. They believe the EyeGate II Delivery System will offer both physicians and patients an important new alternative in advancing the treatment of eye disease.

We provide consulting and services to life science companies in Safety & Risk Management, Scientific Writing, Biometrics and Regulatory Affairs. Read on.

Boston Health Economic Holdings is an independent health analytics company. The company provides innovative healthcare analytics data to better understand the clinical outcomes and value of various patient care strategies. Boston Health Economic Holdings transforms the way analysts from diverse disciplines answer critical questions and make insightful predictions from large, complex databases using their proprietary Instant Health Data (IHD) SaaS platform, that empowers teams within life science companies, health plans, and provider groups to implement deep analytics with little-to-no programming required.

Louis and Clark Pharmacy provides convenient, safe and reliable prescription services for individuals and residential communities in western Massachusetts.

Children & Family Program - Provided outpatient individual and group counseling, case management and support services to at-risk children, adolescents and their parents.

Avila Therapeutics, Inc. designs and develops covalent drugs for viral infections, cancers, and autoimmune diseases. It offers AVL-181, a small molecule hepatitis C virus protease inhibitor. Avila Therapeutics, Inc. has a strategic alliance with Sanofi-Aventis. The company was incorporated in 2006 and is based in Waltham, Massachusetts. As of March 7, 2012, Avila Therapeutics, Inc. operates as a subsidiary of Celgene Corporation.